Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
about
Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytesIron regulatory protein-2 knockout increases perihematomal ferritin expression and cell viability after intracerebral hemorrhage.Conjugation of hydroxyethyl starch to desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolitica infectionIron chelators modulate the fusogenic properties of Salmonella-containing phagosomesPolymeric nanocarriers for the treatment of systemic iron overload.Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders.Polymeric drugs: Advances in the development of pharmacologically active polymers.Cellular iron metabolism in health and disease.Design of clinically useful macromolecular iron chelators.Oxidation-Induced Degradable Nanogels for Iron Chelation3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration.Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups.Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu).Competitive HIF Prolyl Hydroxylase Inhibitors Show Protection against Oxidative Stress by a Mechanism Partially Dependent on Glycolysis.Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung.Genotoxicity of iron chelators in L5178Y mouse lymphoma cells.Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density.Interaction between hydroxyethyl starch and propofol: computational and laboratorial study.Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.(89) Zr- and Fe-Labeled Polymeric Micelles for Dual Modality PET and T1 -Weighted MR Imaging.Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering.
P2860
Q33896718-897CBEA7-2D87-4526-B98B-98DC021E43C7Q33990386-1CE4BB12-2062-4A92-B324-8EB142A5F0D5Q33998385-23D006F7-11FB-4F51-B7B5-5A8409383B65Q35022961-D0BFF4D8-ADED-412D-8ADE-C1623598DAD1Q35673632-1DD37CA5-AFB5-4372-A866-8F25F117BC09Q36210908-C83D0EE9-06BD-4747-86E7-50EBEC757BA3Q36307604-48055711-C68D-424A-8F64-0363223DA417Q37783194-4ACD6A19-3636-462B-8E36-635781471504Q37884088-1EA9FE72-50B7-4CDB-9AED-43A2552C776CQ38379075-F87F0508-1F4A-4EC7-945D-C77E80C78403Q38397352-36049890-E97B-449A-9FB2-6E958557207CQ38989309-2A76F78A-D7A2-4E08-A5FC-9C70257F1B06Q39220645-45957FEF-175D-48CF-B4C2-5E7457C3CB71Q39395748-552DBF92-29A0-481E-8C01-DFC57FF508CDQ39672604-32710C8F-5285-4FBD-9E66-2933CBB4B75BQ39866015-890E43DC-5E90-47BD-B179-082BAE1B65ABQ40829609-B78A66AA-070A-4204-AE28-B0CFFE15DA71Q40871042-1871841E-50A9-473A-B46C-44B3B0251E9CQ43844187-C1BF04E5-0B78-41D4-A73A-8C059B109C80Q47270812-975A5F60-C545-4BDC-82F7-197D4B237A25Q47959708-0A3FBD7D-776E-4D4F-9189-1B93309D443DQ50003300-3E5DD31F-F8AC-4541-A7BE-DF34E38F5AD4Q51107497-7C35F5AB-5CF8-4568-B0C7-13DBE2054531Q51786439-4E6F5037-5F74-4F66-AD18-3AFE39E65D6AQ52591668-EA108E6D-35AE-4762-A591-8D6D9749B18C
P2860
Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
description
1989 nî lūn-bûn
@nan
1989 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@ast
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@en
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@nl
type
label
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@ast
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@en
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@nl
prefLabel
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@ast
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@en
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@nl
P2093
P2860
P356
P1476
Modulation of deferoxamine tox ...... ent to biocompatible polymers.
@en
P2093
B E Hedlund
P E Hallaway
S S Panter
P2860
P304
10108-10112
P356
10.1073/PNAS.86.24.10108
P407
P577
1989-12-01T00:00:00Z